1-2 of 2
Sukjoong Oh, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-139253
Published: 2020
Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Young Rok Do, PhDMD, Jae-Yong Kwak, MD PhD, Hawk Kim, MDPhD, Jeong-A Kim, MD PhD, Hyeoung-Joon Kim, MD PhD, Joon Seong Park, MD, Jooseop Chung, MD PhD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Udomsak Bunworasate, MD, Chul Won Choi, MD PhD, Narcisa Sonia Cornejo Comia, MD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Saengsuree Jootar, MD, Ary Harryanto Reksodiputro, MDPhD, Won-Sik Lee, MD, Yeung-Chul Mun, MD PhD, Jee Hyun Kong, MD, Priscilla B. Caguioa, MD, Jinny Park, MD PhD, Chul W. Jung, MD PhD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2018-99-110568
Published: 2018